The global pharmaceutical dissolution testing services market is expected to garner a market value of USD 693.12 Million in 2023 and is expected to accumulate a market value of USD 1,538.48 Million by registering a CAGR of 8.3% in the forecast period 2023 to 2033.
The growth of the pharmaceutical dissolution testing services market can be attributed to a rise in pharmaceutical research efforts. The market for pharmaceutical dissolution testing services registered a CAGR of 5.2% in the historical period 2018 to 2022.
Due to increased Research and Development expenditure by pharmaceutical companies as well as an increase in the number of novel medications entering the preclinical stage of development, there has also been an increase in demand for pharmaceutical dissolution testing services. The dissolution testing services were initially disturbed due to the pandemic.
| Report Attribute | Details |
|---|---|
| Expected Market Value (2023) | USD 693.12 Million |
| Anticipated Forecast Value (2033) | USD 1,538.48 Million |
| Projected Growth Rate (2023 to 2033) | 8.3% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
According to market research and competitive intelligence provider Future Market Insights- the market for pharmaceutical dissolution testing services reflected a value of 5.2% during the historical period, 2018 to 2022.
The COVID-19 pandemic has significantly impacted the global industry. Pharmaceutical firms, biotech firms, and other end-user demands were primarily served during the crisis by developing coronavirus prevention drugs. Since the end of 2019, these organizations have been actively working toward the development of medications that can be used as a treatment for COVID-19 patients who have only minor symptoms.
And these drug developments require dissolution testing at each stage to access safety, stability, and efficacy, thus contributing to industry growth. Thus, the market for pharmaceutical dissolution testing services is expected to register a CAGR of 8.3% in the forecast period 2023 to 2033.
Research for Prevention of COVID-19 leading to demand for Pharmaceutical Dissolution Testing Services
The pandemic created an increased workload and a reduction in the internal lab testing capacities of various pharmaceutical companies. However, to mitigate or prevent these challenges, various strategies, like rotational shifts, reducing manpower, and working from home were adopted by companies. By the second half of the pandemic, the research studies for drug development started for the prevention of COVID-19 led to a rise in demand for pharmaceutical dissolution testing services. Dissolution testing is an essential tool for assessing the effectiveness of oral solid dose forms.
Its importance is rising due to the fact that medicine must first be released from the product and dissolved in the gastrointestinal fluids before it can be absorbed into the blood vessels to be effective. In other words, how quickly and how much of a medicine is absorbed depends on how easily it dissolves from the dosage form. According to The Food and Drug Administration Dissolution Database, there are 1444 drug products (July 2022) in the database that are in oral solid dose form. The oral solid dose is relatively simple to administer and it is simple to differentiate one oral solid dose product from another.
Marketing Efforts and Awareness regarding Healthcare Products bolstering demand for Pharmaceutical Dissolution Testing Services
Oral solid dose manufacturing approaches are well-developed. Each has a repeatable distribution of ingredients, as well as uniformity in dissolution and bioavailability, to verify that the drug product is safe and effective. The performance of key companies is highly influenced by the level of demand from end users.
Due to intense market efforts, increasing awareness levels, improving accessibility, and government initiatives; consumers, these days, are more concerned about self-care, resulting in higher consumption of healthcare products. The consumption levels are anticipated to rise exponentially over the forecast period.
Principal Consultant
Unskilled Workforce affecting the growth of the Pharmaceutical Dissolution Testing Services Market
The pharmaceutical dissolution testing services are at a nascent stage. Thus, the trial-and-error format of the industry is hampering the overall growth of the market. Moreover, the absence of unskilled labor to perform various testing services tasks is retaining the growth of the market. Although key players are using technology to increase production and testing services, the unavailability of skilled labor is causing losses to the industry.
Research and Development for Novel Therapeutics accelerating market growth in North America
North America is expected to dominate the global industry in 2023 and account for the maximum share exceeding 50% of the overall revenue. The high share of this segment can be attributed to the presence of major companies providing pharmaceutical dissolution testing services and rising investments in Research and Development by them for the development of novel therapeutics for chronic diseases.
In addition, the development of the healthcare system and a rise in the burden of disease have increased the demand for novel therapeutics and, in turn, the demand for laboratory dissolution testing. All these factors are propelling the growth of the pharmaceutical dissolution testing services market in North America.
Government Initiatives for Research and Development supporting the growth of the market in Asia Pacific
The Asia Pacific region is expected to grow at the fastest CAGR during the forecast period owing to the rising investments by companies from developed economies in enhancing regional healthcare. Furthermore, service providers are establishing new facilities and forming alliances to increase the reach of their offerings to various locations in the region.
In addition, the government of the region is focusing on offering investments for research and development that will accelerate the manufacturing of medicines for different ailments. Thus, Asia Pacific is expected to possess a 33% market share for the pharmaceutical dissolution testing services market in Asia Pacific.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
In-vitro dissolution testing is used to evaluate the security of medicines
The in-vitro method segment is expected to dominate the global market in 2023 and account for the largest share of more than 58% of the overall revenue.
The segment is projected to expand further at the fastest growth rate maintaining its leading industry position throughout the forecast period. Two key factors driving the segment growth include an increase in preclinical pipeline capacity and growing awareness about dissolution testing.
In addition, the market for in-vitro pharmaceutical dissolution testing is anticipated to rise as a result of the traditional rising costs of animal tests as well as their socio-ethical problems. Market expansion is predicted to be supported by significant developments in the in-vitro dissolution testing assays used to evaluate the security of medicines and the potential impacts of those drugs on cells and tissues.
To accommodate the rising demand for these assays, businesses are increasing their product lines as the market for in-vitro pharmaceutical dissolution testing expands.
Easy formulation and availability of tablets increasing production of capsules
Based on dosage form, the global industry has been further categorized into capsules, tablets, and others. The other segment includes syrup, ointments, eye/ear/nasal drops, powders, and aerosols.
The tablet dosage form segment is expected to dominate the global industry in 2023 and account for the maximum share of 65% of the overall revenue. The segment is also anticipated to register the fastest CAGR maintaining its leading industry position throughout the forecast period.
This rapid growth can be attributed to the fact that tablets are simple to produce in large quantities, have excellent physical and chemical stability, and can be adjusted for the amount of medicine supplied to the body. The capsules segment is anticipated to register the second-fastest CAGR during the forecast period. Capsules are solid dosage forms. Some of the major drivers of this segment are the stability, easy availability of storage conditions, and easy formulation & development of capsules.
Easy Allowance of pH change maximizing use of paddle for manufacturing tablets
Based on dissolution apparatus, the global industry has been further categorized into basket, paddle, and others. The other segment includes a reciprocating cylinder, flow-through cell, paddle-over disc, rotating cylinder, and reciprocating disc. The paddle segment is expected to dominate the industry and account for the largest revenue share of 70% in 2023.
The paddle is fixed vertically to a motor with variable speed and controlled speed. The tablet or capsule is put into a flask with a circular bottom for dissolving, and the equipment is kept at a steady temperature. This is widely used for the oral solid dosage form.
It is easy to use, can change pH, and can be easily automated for a routine check-up. The basket dissolution apparatus segment is likely to register the second-fastest CAGR during the forecast period. New equipment is positioned at the revolving shaft's end when using the basket dissolution method.
It is made of non-reactive mesh and has a cylindrical form to avoid any unintended chemical interactions that might change the outcome. The main driver for the wide-scale adoption of this method is it can change its pH during the test.
Businesses are undertaking strategies like product launches, M&A agreements, regional expansions, and product launches to gain a competitive edge. Some of the prominent players in the global pharmaceutical dissolution testing services market include Intertek Group Plc, Avivia BV, Almac Group, Agilent Technologies, Inc., Catalent, Inc., Thermofisher Scientific Inc, Cambrex, Charles River Laboratories, Boston Analytical, Pace Analytical Life Sciences, SOTAX, AMRI, SGS SA
| Report Attribute | Details |
|---|---|
| Market Value in 2023 | USD 693.12 Million |
| Market Value in 2033 | USD 1,538.48 Million |
| Growth Rate | CAGR of 8.3% from 2023 to 2033 |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in USD Million and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered | Method, Dosage Form, Dissolution Apparatus, Region |
| Regions Covered | North America; Latin America; Europe; Asia Pacific; Middle East & Africa |
| Key Countries Profiled | USA, Canada, Brazil, Mexico, Germany, United Kingdom, France, Spain, Italy, China, Japan, South Korea, Singapore, Thailand, Indonesia, Australia, New Zealand, GCC Countries, South Africa, Israel |
| Key Companies Profiled | Intertek Group Plc.; Aviva BV; Almac Group; Agilent Technologies, Inc.; Catalent, Inc.; Thermo Fisher Scientific Inc.; Cambrex; Charles River Laboratories; Boston Analytical; Pace Analytical Life Sciences; SOTAX; AMRI; SGS SA |
| Customization | Available Upon Request |
From 2018 to 2022, the pharmaceutical dissolution testing services market grew at a CAGR of 5.2%
The global pharmaceutical dissolution testing services market is expected to grow with an 8.3% CAGR from 2023 to 2033.
As of 2033, the pharmaceutical dissolution testing services market is expected to reach USD 1538.48 Million
The tablet dosage form segment is expected to dominate the global industry in 2023 and account for the maximum share of more than 65% of the overall revenue.
The paddle segment is expected to dominate the industry and account for the largest revenue share of more than 70% in 2023.
The in-vitro method segment is expected to dominate the global market in 2023 and account for the largest share of more than 58% of the overall revenue.
North America is expected to dominate the global industry in 2023 and account for the maximum share of more than 50% of the overall revenue.
Asia Pacific is expected to possess a 33% market share for the pharmaceutical dissolution testing services market in Asia Pacific.
1. Executive Summary 2. Market Overview 3. Market Background 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Method 5.1. In Vitro 5.2. In Vivo 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Dosage Form 6.1. Capsules 6.2. Tablets 6.3. Others 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Dissolution Apparatus 7.1. Basket 7.2. Paddle 7.3. Others 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 8.1. North America 8.2. Latin America 8.3. Europe 8.4. Asia Pacific 8.5. Middle East and Africa (MEA) 9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12. Asia Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14. Key Countries Market Analysis 15. Market Structure Analysis 16. Competition Analysis 16.1. Intertek Group Plc. 16.2. Avivia BV 16.3. Almac Group 16.4. Agilent Technologies, Inc. 16.5. Catalent, Inc. 16.6. Thermo Fisher Scientific Inc. 16.7. Cambrex 16.8. Charles River Laboratories 16.9. Boston Analytical 16.10. SOTAX 16.11. AMRI 16.12. SGS SA 17. Assumptions & Acronyms Used 18. Research Methodology
Explore Healthcare Insights
View Reports
Pharmaceutical Dissolution Testing Services Market
